Transition of T1DM Patients Aged Over 65 Years Into AHCL (780G) Insulin Pump

Diabetes Type 1 Clinical Trial

— 780G65+  

Official title:

Transition of T1DM Patients Aged Over 65 Years Into AHCL (780G) Insulin Pump: the Impact on Glucose Patterns, Quality of Life Physical & Cognitive Measures, as Well as Vascular Status

Clinical Trial Details — Status: Enrolling by invitation

Administrative data

• NCT number: NCT06207838
• Other study ID #: 1072.61201.5.2023
• Status: Enrolling by invitation
• Phase: N/A
• Start date: September 14, 2023
• Est. completion date: December 31, 2024

Study information

• Verified date: January 2024
• Source: Jagiellonian University
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

Older people with diabetes have a higher risk for cognitive impairment and for physical disability whether this may be effected by an improvement in glucose indices is unknown. Thus, the aim of this study is to assess the efficacy of AHCL in people with type 1 diabetes in improving glucose indices, quality of life and physical capacity indices

Description:

Recent advances in insulin pumps, continuous glucose monitoring (CGM) devices, and control algorithms have resulted in an acceleration of progress in the development of the automated systems of insulin delivery including advanced hybrid closed loop (HCL) insulin pumps. The results of the AHCL insulin pump based studies published so far are very encouraging, including that Medtronic-sponsored study performed at our center "Transition of CSII/CGM naïve patients directly into AHCL (780G) insulin pump: the impact on glucose patterns and quality of life measures" (1-6). Unfortunately there is little data concerning the usage of AHCL systems in older patients. The management of these individuals is particularly challenging as older adults with type 1 diabetes are especially vulnerable to hypoglycaemia. The recent ADA/EASD consensus underlines that the use of advanced technologies in older individuals is useful and should not be discontinued or a priori excluded because of the older age (7). Since the AHCL systems are very effective in hypoglycemia prevention they could be considered the treatment of choice in older patients with T1DM. The open question is how effectively would older individuals adopt this advanced technology, how would they accept it, and if the simplicity in terms of everyday usage of AHCL versus less advanced technologies would be appreciated by older individuals with T1DM. Older people with diabetes have a higher risk for cognitive impairment and for physical disability whether this may be effected by an improvement in glucose indices is unknown. Thus, the aim of this study is to assess the efficacy of AHCL in people with type 1 diabetes in improving glucose indices, quality of life and physical capacity indices

Recruitment information / eligibility

• Status: Enrolling by invitation
• Enrollment: 30
• Est. completion date: December 31, 2024
• Est. primary completion date: September 7, 2024
• Accepts healthy volunteers: No
• Gender: All
• Age group: 65 Years and older

Eligibility

Inclusion Criteria:

1. Age over 65 years

2. T1DM

3. Willing to participate in a study for the specified duration

4. Willing to perform = 4 finger stick blood glucose measurements daily

5. Willing to wear the system continuously throughout the study

6. Glycosylated hemoglobin (A1C) value less than 10.0% at time of screening visit

7. Treated with MDI/CSII (with exclusion of 780G)

8. Willing to perform at least 4 BGM/day, when on MDI/CSII

9. Lack of advanced complications of diabetes, eGFR>30

Exclusion Criteria:

1. Severe concurrent illness

2. Laboratory abnormalities, or medications that might affect study participation,

3. Severe renal impairment (eGFR<30)

Related Conditions & MeSH terms

• Diabetes Mellitus, Type 1
• Diabetes Type 1

Intervention

Device:
• MiniMed 780G system
The MiniMed™ 780G system automatically adjust insulin delivery to patient needs for an easier way to stabilise glucose levels. It features an advance level of automation for diabetes management, known as SmartGuard™ technology. If patient glucose levels are trending high, it gives patient more insulin. Technology is CE marked.

Locations

Country	Name	City	State
Poland	Hospital University; Jagiellonian University Medical College	Krakow

Sponsors (2)

Lead Sponsor	Collaborator
Jagiellonian University	Medtronic

Country where clinical trial is conducted

Poland, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Between group difference in the percentage of time spent within range with sensor glucose (SG) between 70-180 mg/dL (TIR) (3.9-10.0 mmol/L).	Between group difference in the percentage of time spent within range with sensor glucose (SG) between 70-180 mg/dL (TIR) (3.9-10.0 mmol/L).	Month 12
Secondary	Between groups difference in the percentage of participants achieving TIR >70%	Between groups difference in the percentage of participants achieving TIR >70%	Month 12
Secondary	Between group difference in the percentage of time spent in hyperglycemic range with SG > 250 mg/dL (13.9 mmol/L)	Between group difference in the percentage of time spent with SG > 250 mg/dL (13.9 mmol/L)	Month 12
Secondary	Between group difference in the percentage of time spent in hyperglycemic range with SG > 180 mg/dL (10.0 mmol/L)	Between group difference in the percentage of time spent with SG > 180 mg/dL (10.0 mmol/L)	Month 12
Secondary	Between group difference in the percentage of time spent in hypoglycemic range with SG < 54 mg/dL (3.0 mmol/L)	Between group difference in the percentage of time spent in hypoglycemic range with SG < 54 mg/dL (3.0 mmol/L)	Month 12
Secondary	Between group difference in the percentage of time spent in hyperglycemic range in hypoglycemic range with SG < 70 mg/dL (3.9 mmol/L)	Between group difference in the percentage of time spent in hyperglycemic range in hypoglycemic range with SG < 70 mg/dL (3.9 mmol/L)	Month 12
Secondary	QoL group difference using: The World Health Organisation- Five Well-Being Index (WHO-5)	QoL group difference (WHO-5): Final score: 0 representing the worst imaginable well-being and 100 representing the best imaginable well-being.	Month 12
Secondary	Differences in baseline vs end of the study in vascular status as measured with LDF: Laser Doppler Flowmetry	Differences in baseline vs end of the study in vascular status as measured with LDF: Laser Doppler Flowmetry	Month 12
Secondary	Differences in baseline vs end of the study in vascular status as measured with FMD: Flow-Mediated Dilatation	Differences in baseline vs end of the study in vascular status as measured with FMD: Flow-Mediated Dilatation	Month 12
Secondary	Differences in baseline vs end of the study in vascular status as measured with IMT-Intima-media thickness	Differences in baseline vs end of the study in vascular status as measured with IMT-Intima-media thickness,	Month 12
Secondary	Difference in physical capacity indices listed in screening visit: 6 Minute Walk Test	Difference in physical capacity indices listed in screening visit: 6 Minute Walk Test (units distance in meters, higher value mean a better outcome)	Month 12
Secondary	Difference in physical capacity indices listed in screening visit: Fried Scale	Difference in physical capacity indices listed in screening visit: Fried Scale (higher scores mean a worse outcome, score >3 frail present)	Month 12
Secondary	Difference in physical capacity indices listed in screening visit: Berg Balance Scale	Difference in physical capacity indices listed in screening visit: Berg Balance Scale (higher score mean a better outcome)	Month 12
Secondary	Difference in physical capacity indices listed in screening visit: Four Square Step	Difference in physical capacity indices listed in screening visit:Four Square Step (units time, shorter time means better outcome)	Month 12